Uromigos-ESMO
ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab Versus Pembrolizumab Alone for Urothelial Carcinoma
Peter O'Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone.Nizar Tannir describes this randomized phase 3 study on bempegaldesleukin plus nivolumab as presented at ESMO.
The phase III PRESTO study examined the effects of androgen suppressants on biochemically relapsed prostate cancer.
Axel Bex summarizes the ipi/nivo, pembro and atezo studies that were presented at ESMO 2022.
Mohamad Allaf gives a recap of the open-label PROSPER study on neoadjuvant nivolumab in RCC.
Chris Sweeney joins to talk about potential highlights to be presented at ESMO 2022.
Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
Dr. Cora Sternber discusses AMG 160 and the future of immunotherapy in CRPC.
Chris Sweeney discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC, a positive R3 trial in the ESMO plenary session.
Dr. Richard Cathomas goes into the detail of chemo immune combinations and what to do next.
Dr. Toni Choueiri and the Uromigos attempt to put the data into context with the other available combinations.
Matt Galsky tries to get to the bottom of whether these data has made any difference in treatment and future plans.
670 Madison Ave.
Manalapan, NJ 07726